What About Biomarkers for Parkinson's Disease?
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Kowal S, Dall T, Chakrabarti R, Storm M, Jain A
. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013; 28(3):311-8.
DOI: 10.1002/mds.25292.
View
2.
El-Agnaf O, Salem S, Paleologou K, Curran M, Gibson M, Court J
. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20(3):419-25.
DOI: 10.1096/fj.03-1449com.
View
3.
Wu Y, Le W, Jankovic J
. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011; 68(1):22-30.
DOI: 10.1001/archneurol.2010.321.
View
4.
Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P
. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002; 59(6):999-1005.
DOI: 10.1001/archneur.59.6.999.
View
5.
Bor-Seng-Shu E, Felicio A, Braga-Neto P, Batista I, Paiva W, Ciampi de Andrade D
. Dopamine transporter imaging using 99mTc-TRODAT-1 SPECT in Parkinson's disease. Med Sci Monit. 2014; 20:1413-8.
PMC: 4138066.
DOI: 10.12659/MSM.890522.
View